What are the benefits for patients?

Population stratification enables vulnerable individuals and their needs to be proactively identified and a more targeted individual response to be delivered from services that are available, to improve both their health and socio-economic outcomes.

What are the benefits for GP Practices and PCN’s?

The Population Stratification report will bring various data sources together to identify vulnerable groups will give practices and PCN’s a better understanding of vulnerable populations and their needs. Services can then be planned and targeted more appropriately. The epidemiology report will allow PCN’s to understand how COVID related mortality and incidence are changing within their geography and explore the characteristics of people who are affected by COVID in their populations. It will also enable PCNs to identify if infection hotspots are occurring in their local geography and respond appropriately.

What are the benefits for the Cheshire and Mersey Region?

Cheshire and Mersey region are responsible for planning enough system capacity to respond to any surge in demand due to the COVID pandemic, whilst also reintroducing planned care capacity cross both acute, community and mental health providers. The demand and capacity report will enable C&M and the sub-regional geographies be sighted on system demand to respond with capacity accordingly.

The list below identifies some of the main categories of benefits for COVID-19 management and beyond:

  • Immediate COVID-19 status for GPs, 111, A&E, OOH etc. Any registered clinician across C&M will be able to see if a citizen has been suspected of COVID-19, tested (with results) or shielded.
  • Analysts will have access to combined near real-time health and social care data to answer questions such as the impact of COVID-19 (or its control measures) on vulnerable or shielded patients and others with complex care needs requiring a system-response.
  • Near real-time pan-C&M dashboards will give managers and planners access to information such as service utilisation, COVID-19 incidence rates and PPE availability with mapping and drill down options.
  • Planners will have consolidated data on the changing healthcare requirements of the population caused by deaths (particularly amongst those with frailty and multimorbidity), changes in supply and use of services, indicators of mental and physical health consequences of isolation and redundancy.
  • Real-time case-find will allow clinicians to identify patients requiring specific plans in response to changing care needs caused by COVID-19.
  • Improved recruitment into national Urgent Public Health COVID-19 studies, and better long-term follow-up data.
  • An advanced data-linkage development site for national studies in partnership with NHSE&I (Ming Tang’s team) and NHSX – including ISARIC CCP-UK.
  • A rapid analytics development site for exploiting system-wide linked data to be shared with other parts of the UK drawing on a high concentration of researchers and service analysts working on national studies.
  • A staging site for refinement of test/track/trace apps/services.
  • A digital platform for public involvement in advancing trustworthy uses of data for better health and care.
  • A digital platform to support innovation and inward investment in life sciences and digital health sectors as part of the COVID-19 Recovery Cells’ work.